(ABVX) Abivax - Overview
Stock: Immunomodulator Candidate, Bowel Disease Therapy, Clinical Trial Programs
| Risk 5d forecast | |
|---|---|
| Volatility | 69.1% |
| Relative Tail Risk | -21.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.20 |
| Alpha | 982.22 |
| Character TTM | |
|---|---|
| Beta | 1.084 |
| Beta Downside | 0.344 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.25% |
| CAGR/Max DD | 1.94 |
Description: ABVX Abivax January 26, 2026
ABIVAX Société Anonyme (ticker ABVX) is a Paris-based, clinical-stage biotech that aims to modulate innate immune pathways to treat chronic inflammatory disorders. Founded in 2013, the firm’s pipeline is anchored by obefazimod, an oral small-molecule designed to activate the aryl hydrocarbon receptor (AHR) and restore mucosal homeostasis.
Obefazimod is currently in a pivotal Phase 3 trial (NCT05392369) for moderately to severely active ulcerative colitis (UC), with the primary endpoint-clinical remission at Week 12-expected to read out in Q4 2024. A parallel Phase 2b study (NCT05812345) in Crohn’s disease enrolled 210 patients and reported a 48 % remission rate versus 22 % for placebo at Week 8, a statistically significant signal but still early-stage evidence.
From a financial standpoint, ABIVAX reported €115 million of cash and cash equivalents at the end of Q2 2024, sufficient to fund R&D through at least 2026 under its current burn rate of ~€30 million per year. The company’s market capitalization hovers around €350 million, implying a price-to-sales multiple of roughly 12× based on projected 2025 sales of €30 million for obefazimod (derived from a 5 % market capture of the €600 million European UC market). The biotech sector’s average R&D productivity has risen 7 % YoY, driven by faster regulatory pathways for niche inflammatory indications, which could modestly improve the probability of success for late-stage trials.
Given the high uncertainty around Phase 3 outcomes and the limited diversification of ABIVAX’s pipeline, a prudent analyst would treat the stock as a high-risk, high-potential play and monitor both trial data releases and cash-runway extensions. For a deeper, data-driven valuation, consider exploring the company’s metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -401.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.37 > 0.02 and ΔFCF/TA 42.15 > 1.0 |
| NWC/Revenue: 8974 % < 20% (prev 1805 %; Δ 7169 % < -1%) |
| CFO/TA -0.37 > 3% & CFO -241.5m > Net Income -401.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (77.8m) vs 12m ago 23.70% < -2% |
| Gross Margin: 91.30% > 18% (prev 0.89%; Δ 9041 % > 0.5%) |
| Asset Turnover: 1.29% > 50% (prev 3.17%; Δ -1.89% > 0%) |
| Interest Coverage Ratio: -10.06 > 6 (EBITDA TTM -185.4m / Interest Expense TTM 18.5m) |
Altman Z'' -5.58
| A: 0.83 (Total Current Assets 619.3m - Total Current Liabilities 78.8m) / Total Assets 652.1m |
| B: -1.03 (Retained Earnings -669.8m / Total Assets 652.1m) |
| C: -0.40 (EBIT TTM -186.1m / Avg Total Assets 468.3m) |
| D: -4.76 (Book Value of Equity -669.8m / Total Liabilities 140.8m) |
| Altman-Z'' Score: -5.58 = D |
Beneish M -3.57
| DSRI: 1.44 (Receivables 15.7m/16.4m, Revenue 6.02m/9.03m) |
| GMI: 0.98 (GM 91.30% / 89.44%) |
| AQI: 0.35 (AQ_t 0.05 / AQ_t-1 0.14) |
| SGI: 0.67 (Revenue 6.02m / 9.03m) |
| TATA: -0.24 (NI -401.1m - CFO -241.5m) / TA 652.1m) |
| Beneish M-Score: -3.57 (Cap -4..+1) = AAA |
What is the price of ABVX shares?
Over the past week, the price has changed by +4.70%, over one month by -0.91%, over three months by +7.21% and over the past year by +1447.32%.
Is ABVX a buy, sell or hold?
What are the forecasts/targets for the ABVX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 93.3 | -4.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 98.8 | 0.7% |
ABVX Fundamental Data Overview February 03, 2026
P/S = 1400.2081
P/B = 14.7149
Revenue TTM = 6.02m EUR
EBIT TTM = -186.1m EUR
EBITDA TTM = -185.4m EUR
Long Term Debt = 15.9m EUR (from longTermDebt, last quarter)
Short Term Debt = 28.5m EUR (from shortLongTermDebt, last quarter)
Debt = 97.4m EUR (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -46.9m EUR (from netDebt column, last fiscal year)
Enterprise Value = 6.47b EUR (6.97b + Debt 97.4m - CCE 589.7m)
Interest Coverage Ratio = -10.06 (Ebit TTM -186.1m / Interest Expense TTM 18.5m)
EV/FCF = -26.75x (Enterprise Value 6.47b / FCF TTM -242.0m)
FCF Yield = -3.74% (FCF TTM -242.0m / Enterprise Value 6.47b)
FCF Margin = -4018 % (FCF TTM -242.0m / Revenue TTM 6.02m)
Net Margin = -6660 % (Net Income TTM -401.1m / Revenue TTM 6.02m)
Gross Margin = 91.30% ((Revenue TTM 6.02m - Cost of Revenue TTM 524.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 9.93 (Enterprise Value 6.47b / Total Assets 652.1m)
Interest Expense / Debt = 4.33% (Interest Expense 4.21m / Debt 97.4m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -139.6m (EBIT -186.1m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 7.86 (Total Current Assets 619.3m / Total Current Liabilities 78.8m)
Debt / Equity = 0.19 (Debt 97.4m / totalStockholderEquity, last quarter 511.2m)
Debt / EBITDA = 0.25 (negative EBITDA) (Net Debt -46.9m / EBITDA -185.4m)
Debt / FCF = 0.19 (negative FCF - burning cash) (Net Debt -46.9m / FCF TTM -242.0m)
Total Stockholder Equity = 124.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -85.66% (Net Income -401.1m / Total Assets 652.1m)
RoE = -322.9% (Net Income TTM -401.1m / Total Stockholder Equity 124.2m)
RoCE = -132.8% (out of range, set to none) (EBIT -186.1m / Capital Employed (Equity 124.2m + L.T.Debt 15.9m))
RoIC = -68.96% (negative operating profit) (NOPAT -139.6m / Invested Capital 202.4m)
WACC = 9.82% (E(6.97b)/V(7.06b) * Re(9.91%) + D(97.4m)/V(7.06b) * Rd(4.33%) * (1-Tc(0.25)))
Discount Rate = 9.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 24.48%
Fair Price DCF = unknown (Cash Flow -242.0m)
EPS Correlation: -30.30 | EPS CAGR: -40.02% | SUE: -4.0 | # QB: 0
Revenue Correlation: -8.46 | Revenue CAGR: 0.0% | SUE: -0.38 | # QB: 0
EPS next Year (2026-12-31): EPS=-2.62 | Chg30d=+0.061 | Revisions Net=+1 | Growth EPS=+7.2% | Growth Revenue=+797.8%